7 Einträge gefunden

1. Update Mammakarzinom 2022 Teil 1 – Brustkrebs in frühen Krankheitsstadien, Update Breast Cancer 2022 Part 1 - Early Stage Breast Cancer

   1. Welslau, Manfred
   2. Müller, Volkmar
   3. Lüftner, Diana
   4. Schütz, Florian
   5. Stickeler, Elmar
   6. Fasching, Peter A
   7. Janni, Wolfgang

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Update Mammakarzinom 2021 Teil 5 – fortgeschrittenes Mammakarzinom, Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer

   1. Lüftner, Diana
   2. Schütz, Florian
   3. Stickeler, Elmar
   4. Fasching, Peter A
   5. Janni, Wolfgang
   6. Kolberg-Liedtke, Cornelia
   7. Kolberg, Hans-Christian

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Update Mammakarzinom 2022 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien, Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer

   1. Müller, Volkmar
   2. Welslau, Manfred
   3. Lüftner, Diana
   4. Schütz, Florian
   5. Stickeler, Elmar
   6. Fasching, Peter A
   7. Janni, Wolfgang

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Update Breast Cancer 2021 Part 4 - Prevention and Early Stages

   1. Thomssen, Christoph
   2. Fehm, Tanja N
   3. Stickeler, Elmar
   4. Fasching, Peter A
   5. Janni, Wolfgang
   6. Kolberg-Liedtke, Cornelia
   7. Kolberg, Hans-Christian

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
5. Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel

   1. Fehm, Tanja N
   2. Stickeler, Elmar
   3. Fasching, Peter A
   4. Janni, Wolfgang
   5. Kolberg-Liedtke, Cornelia
   6. Kolberg, Hans-Christian
   7. Lüftner, Diana

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
6. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"

   1. Schneeweiss, Andreas
   2. Ettl, Johannes
   3. Lüftner, Diana
   4. Beckmann, Matthias W
   5. Belleville, Erik
   6. Fasching, Peter A
   7. Fehm, Tanja N

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
7. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

   1. Schneeweiss, Andreas
   2. Ettl, Johannes
   3. Lüftner, Diana
   4. Beckmann, Matthias W
   5. Belleville, Erik
   6. Fasching, Peter A
   7. Fehm, Tanja N

   2020 - Forschungsinformationssystem des UKE